Full Press Release Details
Media Advisory - Oncolytics Biotech Inc. to Participate in
the LD Micro Invitational Conference
CALGARY, June 2, 2015 /CNW/ - Dr. Brad Thompson, President
and CEO of Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY), will participate in the LD Micro Invitational Conference in a session
on Tuesday, June 2nd, 2015 at 10:30 a.m. PT. The conference takes place from June 1st to 3rd
A live audio link to the webcast session will be available
at http://wsw.com/webcast/ldmicro8/oncy or on the company's website at http://www.oncolyticsbiotech.com/for-investors/presentations.
It is recommended that listeners log on 10 minutes in advance of a live session to register and download any necessary
software. An audio replay will be accessible approximately two hours following the presentation on the Oncolytics website.
About Oncolytics Biotech Inc.
Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics.
Oncolytics' clinical program includes a variety of later-stage, randomized human trials in various indications using REOLYSIN ,
its proprietary formulation of the human reovirus. For further information about Oncolytics, please visit: www.oncolyticsbiotech.com.
The session and webcast times are subject to change. This
release and the presentation related thereto contain forward-looking statements which involve known and unknown risks, delays,
uncertainties and other factors not under the Company's control and which may cause actual results, performance or achievements
of the Company to be materially different from the results, performance or expectations implied by these forward-looking statements.
Such risks and uncertainties include, among others, the efficacy of REOLYSIN as a cancer treatment, the success
and timely completion of clinical studies and trials, uncertainties related to the research and development of pharmaceuticals
and uncertainties related to the regulatory process. Investors should consult the Company's quarterly and annual filings with the
Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking
statements. Investors are cautioned against placing undue reliance on forward-looking statements. The Company does not undertake
to update these forward-looking statements, except as required by applicable laws.
SOURCE Oncolytics Biotech Inc.
For further information: TMX Equicom, Nick Hurst, 300 5th
Ave. SW, 10th Floor, Calgary, Alberta T2P 3C4, Tel: 403.218.2835, Fax: 403.218.2830, nhurst@tmxequicom.com; TMX Equicom, Michael
Moore, San Diego, CA, Tel: 858.886.7813, mmoore@tmxequicom.com; Dian Griesel, Inc., Susan Forman, 335 West 38th Street, 3rd Floor,
New York, NY 10018, Tel: 212.825.3210, Fax: 212.825.3229, sforman@dgicomm.com
CO: Oncolytics Biotech Inc.
CNW 06:30e 02-JUN-15